Home » Business News » 2013 » May » May 13, 2013

MorphoSys Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in Non- Hodgkin's Lymphoma

May 13, 2013 - Martinsried / Munchen, Germany

MorphoSys AG /MorphoSys Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in Non-Hodgkin'sLymphoma. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) announced todaythat ithas dosed the first patient in a Phase 2 clinical trial of MOR208 inNon-Hodgkin's Lymphoma (NHL). MOR208 is a potent Fc-optimized anti-CD19antibody towhich MorphoSys gained worldwide rights via an exclusive licenseandcollaboration agreement with Xencor in 2010.

The open-label, multicenter, single-arm clinical trial is designed toassess theefficacy of MOR208 in patients with relapsed or refractory Non-Hodgkin'sLymphoma. Secondary outcome measures include response duration,safety andpharmacokinetics of MOR208. A total of up to 120 patients are plannedto beenrolled in four separate sub-indications (FL, MCL, DLBCL and otherforms ofindolent NHL). More information on the trial can be found bysearching forMOR208 at The trial is to be conducted at sitesacrossboth Europe and the US.

"In MOR208 we have a very exciting cancer program with a hugepotential.Evaluating MOR208 in NHL and B-ALL - building on the data we alreadyhave forCLL - should enable us to assess the therapeutic benefit and broadercommercialpotential of the molecule in hematological malignancies," commented Dr.ArndtSchottelius, Chief Development Officer of MorphoSys AG. "Broadening thedrug'sdevelopment program into additional indications is intended tomaximize thevalue of this compound."

MOR208 showed encouraging signs of preliminary anti-tumor activityand anacceptable safety and tolerability profile in a Phase 1/2a trial inpatientswith high-risk, heavily pretreated chronic lymphocytic leukemia (CLL) orsmalllymphocytic lymphoma (SLL). In addition to the phase 2 trial in NHL,MorphoSysis currently evaluating the compound in a phase 2 trial in B-cellAcuteLymphoblastic Leukemia (B-ALL).

B-cell malignancies, such as B-ALL, NHL and CLL affect more than onehundred andfifty thousand patients in the seven major markets each year. Thetargetmolecule CD19 is expressed more broadly and earlier in B-cell developmentthanCD20, the target of the marketed cancer drug Rituxan®. ThereforetargetingCD19 could potentially allow for an even broader therapeutic use of MOR208thanmarketed anti-CD20 antibodies.

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technologyinthe pharmaceutical industry. By successfully applying this and otherpatentedtechnologies, MorphoSys has become a leader in the field of therapeuticantibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built atherapeuticpipeline of more than 70 human antibody drug candidates for the treatmentofcancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.Withits ongoing commitment to new antibody technology and drug development,MorphoSys is focused on making the healthcare products of tomorrow.MorphoSys islisted on the Frankfurt Stock Exchange under the symbol MOR. For regularupdatesabout MorphoSys, visit

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®,arYla®,Ylanthia® and 100 billion high potentials® are registeredtrademarks ofMorphoSys AG.

Slonomics® is a registered trademark of Sloning BioTechnologyGmbH, asubsidiary of MorphoSys AG.

This communication contains certain forward-looking statementsconcerning theMorphoSys group of companies. The forward-looking statements containedhereinrepresent the judgment of MorphoSys as of the date of this release andinvolverisks and uncertainties. Should actual conditions differ from theCompany'sassumptions, actual results and actions may differ from thoseanticipated.MorphoSys does not intend to update any of these forward-lookingstatements asfar as the wording of the relevant press release is concerned.

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE[HUG#1700850]

Media Release (PDF):

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Loser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
Email Contact


Comment on this story